1Koch Institute for Integrative Cancer Research, Massachusetts Institute for Technology, Cambridge, Massachusetts. 2Department of Biological Engineering, Massachusetts Institute for Technology, ...
ApexOnco and other media outlets reported that the FDA has placed a partial clinical hold on the phase III IDeate-Lung02 trial after more patients died from interstitial lung disease than anticipated; ...
Main Finding: A phase I/II trial supported the safety and efficacy of intermittent administration of VT3989 for the treatment of mesothelioma. Concept: Blocking TEAD autopalmitoylation effectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback